Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Australia
  4. Australian Stock Exchange
  5. Next Science Limited
  6. Company
    NXS   AU0000041329

NEXT SCIENCE LIMITED

(NXS)
  Report
Delayed Australian Stock Exchange  -  12:10 2022-12-09 am EST
0.7000 AUD    0.00%
10/27Transcript : Next Science Limited Presents at ShareCafe Small Cap "Hidden Gems" Webinar, Oct-27-2022 09:30 PM
CI
10/19Next Science's Collagen Products Secure Medicare Accreditation in the US; Shares Jump 8%
MT
10/18Next Science Limited Announces the Launch of Topical Collagen Products
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Business Summary
Next Science Limited is an Australia-based medical technology company. The Company's principal activities include development and commercialization of XBIO technology. The XBIO technology is a non-toxic technology used in solving the problems of bacterial biofilms. The CompanyÔÇÖs products include XPERIENCE, Blast X, SurgX and Bactisure. The XPERIENCE product is an antimicrobial solution used to prevent surgical site infections by rinsing away debris and microorganisms. SurgX Sterile Antimicrobial Gel is used to reduce surgical site and post-surgical infections by destroying planktonic and biofilm-based bacteria within the gel with sustained effectiveness for up to five days. The Blast X is an antimicrobial wound gel.
Sales per Business
20202021Delta
Technologies with Bacterial Issue Application5.00100%11.92100% +138.5%
AUD in Million
Sales per region
20202021Delta
United States4.8797.5%11.8099% +142.18%
Australia0.132.5%0.121% -2.22%
AUD in Million
Managers
Name Title Age Since
Judith Mitchell Chief Executive Officer, Director & MD - 2017
Jacqueline Butler Chief Financial Officer - 2017
Matthew Myntti, Dr. Chief Technology Officer - 2017
Jeanne Lee VP-Regulatory Affairs & Clinical Operations - 2019
Jon Swanson Chief Operating Officer - 2018
Gillian Maria Nairn Secretary - -
Michael Morello Vice President-Sales - 2021
Members of the board
Name Title Age Since
Mark Compton Independent Non-Executive Chairman 60 2021
Dan Spira Independent Non-Executive Director - 2017
Aileen Stockburger Independent Non-Executive Director 59 2018
Judith Mitchell Chief Executive Officer, Director & MD - 2017
Bruce Alan Hancox Non-Executive Director - -
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 214,790,134 101,932,149 47.5% 0 0.0% 47.5%
Shareholders
NameEquities%
Langley Alexander Walker 83,547,062 38.9%
Matthew Myntti 12,774,989 5.95%
Judith Mitchell 6,420,000 2.99%
Norges Bank Investment Management 5,086,236 2.37%
Wittenoom Charles Dirck 3,000,000 1.40%
Scone Investments Pty Ltd. 1,159,452 0.54%
GNR Superannuation Fund 965,000 0.45%
Ka Tet Pty Ltd. 890,500 0.41%
Desiree Hancox Darroch 887,500 0.41%
Dan Spira 752,172 0.35%
Company contact information
Next Science Ltd.
Tower A, The Zenith Building
821 Pacific Highway
Level 19, Suite 1902
Chatswood, New South Wales (NSW) 2067

Phone : +61.2.8607.5124
Web : http://www.nextscience.com
Brand Portfolio
In partnership withAllbrands.markets
More brands of Next Science Limited
Sector Other Pharmaceuticals
1st jan.Capi. (M$)
NEXT SCIENCE LIMITED-43.78%102
JOHNSON & JOHNSON3.57%463 286
ELI LILLY AND COMPANY34.66%353 267
ABBVIE INC.22.59%293 450
PFIZER, INC.-14.92%290 657
NOVO NORDISK A/S22.08%287 434
MERCK & CO., INC.44.64%281 049
ROCHE HOLDING AG-20.09%267 313
ASTRAZENECA PLC30.40%214 308
NOVARTIS AG6.25%196 152
BRISTOL-MYERS SQUIBB COMPANY28.20%177 305
AMGEN INC.27.02%152 374
SANOFI0.47%117 709
GILEAD SCIENCES, INC.20.91%112 217
GSK PLC-9.73%73 637
DAIICHI SANKYO CO., LTD.50.97%61 981
BAYER AG12.19%54 633
TAKEDA PHARMACEUTICAL COMPANY LIMITED28.12%45 745
CHUGAI PHARMACEUTICAL CO., LTD-3.43%43 443
JIANGSU HENGRUI MEDICINE CO., LTD.-23.35%35 592
ASTELLAS PHARMA INC.13.61%28 357